Koesten, Hirschmann & Crabtree, Inc. Arrowhead Pharmaceuticals, Inc. Transaction History
Koesten, Hirschmann & Crabtree, Inc.
- $192 Million
- Q2 2025
A detailed history of Koesten, Hirschmann & Crabtree, Inc. transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Koesten, Hirschmann & Crabtree, Inc. holds 47 shares of ARWR stock, worth $1,697. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47Holding current value
$1,697% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ARWR
# of Institutions
321Shares Held
99.1MCall Options Held
444KPut Options Held
568K-
Black Rock Inc. New York, NY15.7MShares$566 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.5MShares$561 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY10.6MShares$383 Million3.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$230 Million0.0% of portfolio
-
Slate Path Capital LP New York, NY5.23MShares$189 Million1.65% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $3.82B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...